6/22 Early treatment study
et al., medRxiv, doi:10.1101/2020.06.19.20136093 (Preprint)
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (HCQ), p=0.01. 67 patients with mild/moderate cases.
Chen et al., 6/22/2020, Randomized Controlled Trial, China, Asia, preprint, 19 authors, dosage 200mg bid days 1-10.
median time to PCR-, 72.0% lower, relative time 0.28, p = 0.01, treatment 18, control 12.
